Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Capital Expenditures (2016 - 2025)

Editas Medicine (EDIT) has disclosed Capital Expenditures for 11 consecutive years, with $547000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures rose 110.46% to $547000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $478000.0, a 119.65% increase, with the full-year FY2024 number at $65000.0, down 92.31% from a year prior.
  • Capital Expenditures was $547000.0 for Q3 2025 at Editas Medicine, up from -$69000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $7.4 million in Q4 2021 to a low of -$5.2 million in Q3 2024.
  • A 5-year average of $639647.1 and a median of $370000.0 in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: soared 3993.06% in 2023, then plummeted 2288.7% in 2024.
  • Editas Medicine's Capital Expenditures stood at $7.4 million in 2021, then crashed by 127.83% to -$2.1 million in 2022, then decreased by 24.98% to -$2.6 million in 2023, then skyrocketed by 97.31% to -$69000.0 in 2024, then skyrocketed by 892.75% to $547000.0 in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Capital Expenditures are $547000.0 (Q3 2025), -$69000.0 (Q4 2024), and -$5.2 million (Q3 2024).